Compare Amgen, Inc. (AMGN) vs iShares Global Tech ETF (IXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares Global Tech ETF — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while iShares Global Tech ETF trades at $138.25. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares Global Tech ETF pays none. Which is the better fit depends on your goals.
| AMGN | IXN | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $149.74 |
52-Week Low | $271.18 | $93.09 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IXN trades at $140.73 with a slight 0.21% daily gain, showing bullish technical momentum with strong moving average support. The ETF maintains a neutral oscillator reading while offering global tech exposure. Recent dividend activity and mixed analyst sentiment reflect the current market positioning near key resistance levels.
The outlook remains cautiously optimistic given strong technical momentum, though valuation concerns and high expectations present near-term risks. Investment opportunity lies in continued tech sector leadership, while concentration risk and stretched valuations require careful monitoring for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →
